These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 19952425

  • 1. Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats.
    Kadowaki D, Anraku M, Tasaki Y, Taguchi K, Shimoishi K, Seo H, Hirata S, Maruyama T, Otagiri M.
    Biol Pharm Bull; 2009 Dec; 32(12):2041-5. PubMed ID: 19952425
    [Abstract] [Full Text] [Related]

  • 2. An angiotensin II type-I receptor blocker, olmesartan medoxomil, attenuates lipid peroxidation in renal injury induced by subtotal nephrectomy.
    Takahashi T, Konta T, Takasaki S, Ichikawa K, Takeishi Y, Kubota I.
    Clin Exp Nephrol; 2007 Sep; 11(3):202-208. PubMed ID: 17891346
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes.
    Mizuno M, Sada T, Kato M, Koike H.
    Hypertens Res; 2002 Mar; 25(2):271-8. PubMed ID: 12047043
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.
    Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y, Ishikawa N, Yuzawa H, Koike H, van Ypersele de Strihou C, Kurokawa K.
    J Am Soc Nephrol; 2003 May; 14(5):1212-22. PubMed ID: 12707391
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of Olmesartan on serum cystatin C levels in the patients with essential hypertension.
    Koc Y, Mazi E, Sakaci T, Basturk T, Damar AB, Ahbap E, Unsal A, Borlu F.
    Eur Rev Med Pharmacol Sci; 2011 Dec; 15(12):1389-94. PubMed ID: 22288300
    [Abstract] [Full Text] [Related]

  • 14. Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan.
    Iwamoto M, Hirohata S, Ogawa H, Ohtsuki T, Shinohata R, Miyoshi T, Hatipoglu FO, Kusachi S, Yamamoto K, Ninomiya Y.
    Hypertens Res; 2010 Dec; 33(12):1305-11. PubMed ID: 20944640
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Olmesartan ameliorates progressive glomerular injury in subtotal nephrectomized rats through suppression of superoxide production.
    Fujimoto S, Satoh M, Horike H, Hatta H, Haruna Y, Kobayashi S, Namikoshi T, Arakawa S, Tomita N, Kashihara N.
    Hypertens Res; 2008 Feb; 31(2):305-13. PubMed ID: 18360051
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats.
    Gorain B, Choudhury H, Kundu A, Sarkar L, Karmakar S, Jaisankar P, Pal TK.
    Colloids Surf B Biointerfaces; 2014 Mar 01; 115():286-94. PubMed ID: 24388859
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.